Alexandria Real Estate Equities Faces Class Action Lawsuit with No Out-of-Pocket Costs for Investors
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5d ago
0mins
Source: PRnewswire
- Class Action Notification: Rosen Law Firm reminds investors who purchased Alexandria Real Estate Equities securities between January 27, 2025, and October 27, 2025, that they must apply to be lead plaintiffs by January 26, 2026, to participate in the class action and seek compensation.
- No Out-of-Pocket Costs: Participants can receive compensation without any upfront fees through a contingency fee arrangement, which reduces the financial burden on investors and encourages more affected individuals to join the lawsuit.
- False Information Disclosure: The lawsuit alleges that Alexandria Real Estate provided overly positive statements regarding its leasing activities and financial growth while concealing significant adverse facts about its Long Island City property, resulting in investor losses.
- Law Firm Background: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its strength and experience in handling such cases.
Analyst Views on ARE
Wall Street analysts forecast ARE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ARE is 64.78 USD with a low forecast of 30.00 USD and a high forecast of 104.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Analyst Rating
2 Buy
9 Hold
1 Sell
Hold
Current: 53.270
Low
30.00
Averages
64.78
High
104.00
Current: 53.270
Low
30.00
Averages
64.78
High
104.00
About ARE
Alexandria Real Estate Equities, Inc. is a life science real estate investment trust. The Company is an owner, operator and developer of collaborative life science, agricultural technology (agtech), and advanced technology mega campuses in AAA innovation cluster locations, including Greater Boston, the San Francisco Bay Area, New York City, San Diego, Seattle, Maryland, and Research Triangle. The Company, through its venture capital platform, provides strategic capital to life science, agrifoodtech, climate innovation, and technology companies. Its tenants include multinational pharmaceutical companies; public and private biotechnology companies; life science product, service and medical device companies; digital health, technology, and agtech companies; academic and medical research institutions; United States government research agencies; non-profit organizations, and venture capital firms. It has a Labspace asset base predominantly concentrated in markets with barriers to entry.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
